Latest Survey Reveals Bladder and Ureter Cancer Drug Development Pipeline Review, 2017 | Researchmoz

Researchmoz added Most up-to-date research on "Bladder and Ureter Cancer Drug Development Pipeline Review, 2017" to its huge collection of research reports.

This report provides an overview of the bladder and ureter pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for these two indications, and features dormant and discontinued projects.

Bladder cancer occurs in tissues of the urinary bladder. Symptoms include blood or blood clots in the urine, frequent urination, lower back pain on one side of the body and burning during urination. There are a total of 223 products in development for this indication, by 158 companies and 19 academic institutions. Key companies active in this space include F. Hoffmann-La Roche, GlaxoSmithKline, AstraZeneca, MedImmune and Pfizer.

To Get Sample Copy of Report visit @ https://www.researchmoz.us/enquiry.php?type=S&repid=1497547

Ureter or ureteral cancer affects the ureter, the tube that transports urine from the kidney to the urinary bladder. Symptoms and signs of urethral cancer include bleeding from the urethra or blood in the urine, discharge from the urethra and enlarged lymph nodes in the groin area. This pipeline is far smaller; there are a total of nine products in development for this indication, by six companies and two academic institutions.

Scope

- Which companies are the most active within each pipeline?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in this disease area?

Reasons to buy

- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Contents

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 8

2 Introduction 9
2.1 Bladder and Ureter Cancer Report Coverage 9
2.2 Ureter Cancer – Overview 9
2.3 Bladder Cancer – Overview 9

3 Therapeutics Development 10
3.1 Ureter Cancer 10
3.2 Bladder Cancer 14

Get Complete TOC With Tables and Figures @ https://www.researchmoz.us/bladder-and-ureter-cancer-drug-development-pipeline-review-2017-report.html/toc

4 Therapeutics Assessment 34
4.1 Ureter Cancer 34
4.2 Bladder Cancer 41

5 Companies Involved in Therapeutics Development 58
5.1 Ureter Cancer 58
5.2 Bladder Cancer 61

6 Dormant Projects 125
6.1 Bladder Cancer 125

7 Discontinued Products 131
7.1 Bladder Cancer 131

Continue...

About ResearchMoz

ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.

ResearchMoz
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Email: sales@researchmoz.us
Website @ https://www.researchmoz.us/
Tel: 866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-621-2074
Follow us on LinkedIn @ http://bit.ly/1TBmnVG

This release was published on openPR.